Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend
Authors' conclusion
In conclusion, abaloparatide increased TBSth rapidly and progressively over 18 months and increments were maintained over 2 years with alendronate. TBSth increase was associated with vertebral fracture risk reduction.
Study context
- Population
- Women with osteoporosis randomised in ACTIVE, followed in ACTIVExtend, with evaluable trabecular bone score (TBS)
- Participants
- 911 women
- Comparison
- Abaloparatide vs placebo for 18 months, followed by alendronate for 24 months
- Primary endpoint
- Change in TBS adjusted for tissue thickness (TBSth) from baseline
- Follow-up
- Baseline, 6, 18 and 43 months
Primary result
As reported in the abstract
Cumulative TBSth increase · 43 months (18 months + 2 years alendronate)
P < 0.001
- Mean TBSth increase after 18 months abaloparatide (p < 0.001); unchanged with placebo
- 4%
Further findings
Degraded TBSth (<1.027) · 43 months
P < 0.05
- Degraded TBSth (<1.027) — Degraded TBSth at baseline
- 42%
Abaloparatide-treated women with TBSth increase ≥ least significant change (LSC) at 18 months, and vertebral fracture
- Abaloparatide-treated women with TBSth increase ≥ LSC at 18 months
- 50%
- OR of vertebral fracture, 6 months
- 0.19 (95% CI 0.04-0.80)
- OR of vertebral fracture, 43 months
- 0.30 (95% CI 0.11-0.79)
- Adjusted for baseline age and spine bone mineral density (BMD)
Original publication
Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend. J Bone Miner Res. Published 1 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →